STXS

AI Memo

Stereotaxis

As of 2026-08-01/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-01 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Second-quarter 2026 results scheduled • 2026-08-11

Base target: $2 / p=50% prob

Biggest risk

Q1 revenue declined year over year, the company cited manufacturing and implementation friction, and the Johnson & Johnson relationship wind-down creates a revenue headwind. Acquisition integration, supply scaling, and hospital adoption could disappoint.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Regulatory momentum, high reported MAGiC demand, Synchrony shipments, and Robocath could create a broader robotic endovascular platform and support a disposable-revenue transition.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-01

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

MAGiC catheter supply and adoption ramp
Synchrony and GenesisX commercialization
Regulatory momentum, high reported MAGiC demand, Synchrony shipments, and Robocath could create a broader robotic endovascular platform and support a disposable-revenue transition.

BearKey bullets

Hospital adoption and GenesisX placement timing remain uncertain.
Low analyst coverage and unavailable market-reaction, options, short-interest, and social data reduce confidence.
Manufacturing capacity and product rollout may lag demand expectations.

WatchKey bullets

Second-quarter 2026 results scheduled

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $2 (p=50%)

Target spread vs base: +40% / -43%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $2 (p=50%)Bear Target: $1 (p=25%)

Commentary

Primary-source tone is cautiously positive on regulatory approvals, product demand, and the Robocath strategy, but Q1 operating performance was mixed and commercialization remains early. Social, options, short-interest, employee, and post-event price-reaction data are unavailable; the scheduled earnings checkpoint and low coverage support a monitoring-oriented, speculative interpretation rather than a high-conviction thesis.

As of 2026-08-01 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Regulatory momentum, high reported MAGiC demand, Synchrony shipments, and Robocath could create a broader robotic endovascular platform and support a disposable-revenue transition.

Bear Case

Drivers

Scannable catalysts and supporting factors

MAGiC catheter supply and adoption ramp
Synchrony and GenesisX commercialization

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Analysis 2026-08-01 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

65.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-11
Second-quarter 2026 results scheduled
Stereotaxis plans to report second-quarter 2026 results on August 11, 2026. The release is a defined near-term checkpoint for revenue, commercialization progress, and Robocath integration commentary, but consensus and expected surprise data are unavailable [#PR-EARNINGS-2026-07-21].
Prob 100.00% • Move 10.00% • Priced-in 35.00%
EVENT2026-12-31
Robocath integration and platform expansion
The Robocath acquisition creates a complementary robotic platform for endovascular procedures. Integration milestones and evidence of commercial or strategic benefits are potential sentiment drivers, while transaction and execution risks remain material [#8-K-2026-07-16].
Prob 60.00% • Move 18.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

MAGiC catheter supply and adoption ramp
2026-12-31
MAGiC has U.S. FDA approval, is being used at multiple U.S. and European sites, and management reported demand exceeding supply while targeting manufacturing capacity of 500 catheters per month by year-end. Execution remains unproven [#SEC-8K-2026-05-12].
Prob 65% • Move 25% • Priced-in 35%

Long-term Catalysts

Months to a year

Synchrony and GenesisX commercialization
2027-12-31
Synchrony received FDA clearance with initial orders and shipments ongoing, while the company is preparing for GenesisX placements. Successful adoption could validate the broader product ecosystem, but timing and scale are uncertain [#SEC-8K-2026-05-12].
Prob 40% • Move 35% • Priced-in 25%

Risks

Hospital adoption and GenesisX placement timing remain uncertain.
Low analyst coverage and unavailable market-reaction, options, short-interest, and social data reduce confidence.
Manufacturing capacity and product rollout may lag demand expectations.
Revenue remains exposed to the Johnson & Johnson relationship wind-down and uneven system placements.
Robocath integration could add execution, financing, and operational complexity.

Peers

Symbol	Summary
CVRX	Closest supplied small-cap medtech reference for commercialization and adoption risk, though it is not a direct product peer.
MBOT	Small-cap medical-device reference with some procedural-technology relevance, but direct comparability and coverage are limited.
BSX	Large cardiovascular and interventional-device reference; useful for hospital workflow and endovascular adoption context, not valuation or size comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-01

Loading AI feed…

Symbol

Summary

CVRX

Closest supplied small-cap medtech reference for commercialization and adoption risk, though it is not a direct product peer.

MBOT

Small-cap medical-device reference with some procedural-technology relevance, but direct comparability and coverage are limited.

BSX

Large cardiovascular and interventional-device reference; useful for hospital workflow and endovascular adoption context, not valuation or size comparison.